NCT00669812Unknown2 期
A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Survival at 1 year
研究概览
简要总结
RATIONALE: Giving chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
PURPOSE: This phase II trial is studying high-dose chemotherapy given together with peripheral blood stem cell transplant in treating patients with intestinal T-cell lymphoma.
详细描述
OBJECTIVES:
Primary
- To assess the efficacy and toxicity of intensive high-dose chemotherapy (alternating I'VE regimen and intermediate-dose methotrexate) followed by autologous peripheral blood stem cell transplantation for treatment of patients with intestinal T-cell lymphoma.
Secondary
- To assess the toxicity of the regimen in a large population of these patients.
- To provide a coordinated approach to the treatment of these patients.
- To register patients unfit for the protocol chemotherapy into the pathological part of the study.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Newly confirmed diagnosis of intestinal T-cell lymphoma/ enteropathy-type T-cell lymphoma according to the following WHO classifications:
- •Usual phenotype CD3-, CD7-positive; CD5-, CD4-, CD8-negative; or CD30-positive
- •Complete surgical resection allowed
- •PATIENT CHARACTERISTICS:
- •Unsupported neutrophils ≥ 1,500/mm^3 unless attributed to lymphomatous bone marrow infiltration
- •Unsupported platelets ≥ 100,000/mm^3 unless attributed to lymphomatous bone marrow infiltration
- •Creatinine clearance ≥ 50 mL/min
- •Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)
- •Bilirubin ≤ 2.5 times ULN
- •Left ventricular ejection fraction ≥ 50%
- •Not pregnant or nursing
- •Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment
- •Patients with any serious concomitant medical or psychiatric condition that would preclude them tolerating the planned treatment should be entered into the registration study only
- •No known hepatitis B, hepatitis C, or HIV positivity
- •No active uncontrolled cardiovascular disease
- •No abnormal EKG if there is a previous history of cardiac problems
- •No other severe impairment of cardiac function
- •No active malignancy within the past 5 years except cervical intraepithelial neoplasia or localized skin cancer
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •Prior diagnostic or emergency surgical procedures allowed
- •More than 5 years since prior treatment for malignancy
- •No prior chemotherapy or radiotherapy for treatment of lymphoma
排除标准
- 未提供
结局指标
主要结局
Survival at 1 year
次要结局
- Toxicity
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT00275015German CLL Study Group169
已完成
不适用
High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's LymphomaLymphomaNCT00544570City of Hope Medical Center30
已完成
1 期
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerFallopian Tube CancerOvarian CancerPeritoneal Cavity CancerNCT00550784City of Hope Medical Center8
Unknown
2 期
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin LymphomaLymphomaNCT00908180Cancer Research UK47
Unknown
2 期
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin LymphomaLymphomaNCT00907036Cancer Research UK49